Current Nevirapine News and Events

Current Nevirapine News and Events, Nevirapine News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 3 | 96 Results
Drugs used to treat HIV and flu can have detrimental impact on crops
Scientists from the UK and Kenya found that lettuce plants exposed to a higher concentration of four commonly-used antiviral and antiretroviral medicines could be more than a third smaller in biomass than those grown in a drug-free environment. (2021-01-28)

Does timing matter for initiating HIV therapy in infants?
Results of a trial in newborns with HIV who started antiretroviral therapy within 14 days of birth showed that about 75 percent attained viral suppression on ART; but only 52 percent sustained suppression on ART. Success was similar in infants starting ART less than two days old (51%) and in infants starting therapy between 2 and 14 days after birth (54%). Very early ART on its own is unlikely to lead to remission. (2020-01-07)

HIV therapy for breastfeeding mothers can virtually eliminate transmission to babies
For HIV-infected mothers whose immune system is in good health, taking a three-drug antiretroviral regimen during breastfeeding essentially eliminates HIV transmission by breast milk to their infants, according to results from a large clinical trial conducted in sub-Saharan Africa and India. (2016-07-18)

EGPAF wins award to scale up innovative PMTCT medications in Uganda
The Elizabeth Glaser Pediatric AIDS Foundation has been selected to receive the prestigious Saving Lives at Birth: A Grand Challenge for Development Award for its model to nationally scale up use of the innovative 'Pratt Pouch' to prevent mother-to-child transmission of HIV in Uganda. EGPAF's model will introduce the easy-to-use pouches during antenatal care, delivery, and postnatal care services in Uganda with the goal of reaching 40,000 infants in three years. (2016-03-24)

The Lancet: Breastfeeding babies protected against HIV infection from their HIV-positive mothers with 12 months of liquid antiretroviral drug treatment
A study from four countries in Africa, published in The Lancet, shows that providing babies with up to 12 months of liquid formula HIV drugs, while breastfeeding with their HIV-positive mothers, is highly effective at protecting them from infection, including in the 6- to 12-month period after birth which has not been analyzed in previous research. The study is by Professor Philippe Van de Perre, INSERM, Montpellier, France, and colleagues. (2015-11-18)

Study shows effectiveness of switching antiretroviral therapy for HIV-infected children
A Columbia University study evaluated whether HIV-infected children in South Africa who had achieved viral suppression with one antiretroviral treatment could transition to efavirenz-based therapy, the recommended drug for children older than three years, without risk of viral failure. The researchers reported that the treatment program resulted in excellent sustained virological control. (2015-11-04)

Effectiveness of efavirenz-based antiretroviral therapy for HIV-infected children
Louise Kuhn, Ph.D., of Columbia University, New York, and colleagues evaluated whether HIV-infected children in South Africa who had achieved viral suppression with one treatment could transition to efavirenz-based therapy without risk of viral failure. The study appears in the Nov. 3 issue of JAMA. (2015-11-03)

Anti-HIV drug for adults is safe, effective in children exposed to nevirapine in the womb
HIV-infected children exposed in the womb to nevirapine, a drug used to prevent mother-to-child HIV transmission, can safely and effectively transition to efavirenz, a similar drug recommended for older children and adults, according to a study funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the National Institutes of Health. (2015-11-03)

NIH-sponsored study identifies superior drug regimen for preventing mother-to-child HIV transmission
For HIV-infected women in good immune health, taking a three-drug regimen during pregnancy prevents mother-to-child HIV transmission more effectively than taking one drug during pregnancy, another during labor and two more after giving birth, an international clinical trial has found. (2014-11-17)

Risk of birth defects small with HIV drugs
The risks of birth defects in children exposed to antiretroviral drugs in utero are small when considering the clear benefit of preventing mother-to-child transmission of HIV but where there are safe and effective alternatives, it might be appropriate to avoid use by pregnant women of drugs that may be associated with elevated risks of birth defects, such as zidovudine and efavirenz, according to a study published by French researchers published in this week's PLOS Medicine. (2014-04-29)

Antiretroviral regimen associated with less virological failure among HIV-infected children
Elizabeth D. Lowenthal, M.D., M.S.C.E., of the University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, and colleagues conducted a study to determine whether there was a difference in time to virological failure between HIV-infected children initiating nevirapine vs. efavirenz-based antiretroviral treatment in Botswana. (2013-04-30)

Study finds less-used regimen for treating children in Africa with HIV is more effective
The first large-scale comparison of first-line treatments for HIV-positive children finds that initial treatment with efavirenz is more effective than nevirapine in suppressing the virus in children ages three to 16. However, the less effective nevirapine is currently used much more often in countries with a high prevalence of HIV. The study has the potential to change the standard of care in the parts of the world where most HIV-infected children live. (2013-04-30)

Early antiretroviral treatment reduces viral reservoirs in HIV-infected teens
A new study led by University of Massachusetts Medical School professor and immunologist Katherine Luzuriaga, MD, and Johns Hopkins Children's Center virologist Deborah Persaud, MD, highlights the long-term benefits of early antiretroviral therapy initiated in infants. (2013-03-04)

HIV treatment reduces risk of malaria recurrence in children, NIH funded study shows
A combination of anti-HIV drugs has been found to also reduce the risk of recurrent malaria by nearly half among HIV-positive children, according to researchers supported by the National Institutes of Health. (2012-11-28)

First antibiotic stewardship probed in the Journal of the Pediatric Infectious Diseases Society
The articles address: Impact of prospective-audit-with-feedback program and clinician attitudes toward program. (2012-08-09)

Drug combo much better than AZT alone at preventing mother-to-infant HIV transmission
A two- or three-drug combination within 48 hours or birth to infants born of HIV-positive mothers can reduce the risk of intrapartum HIV acquisition by about half, compared to AZT alone. (2012-06-20)

Adding nevirapine to HIV regimen halves newborn transmission rate
Adding the drug nevirapine to the regimen given to newborns of women diagnosed with HIV shortly before or during labor halves the newborns' risk of contracting the virus, according to findings by a National Institutes of Health research network. (2012-06-20)

Nevirapine based treatment for HIV is effective in African women
In African women, an anti-AIDS treatment regimen that includes the drug nevirapine is as effective as a treatment regimen with the more expensive drugs, lopinavir/ritonavir, according to a study by a team of international researchers published in this week's PLoS Medicine. (2012-06-12)

Nevirapine-based treatment is effective in African women, but not optimal
According to new research from Brigham and Women's Hospital, an anti-AIDS treatment regimen, which includes the WHO-recommended drug nevirapine, is just as effective at suppressing the HIV virus as lopinavir/ritonavir, which is more expensive. (2012-06-12)

Pre-existing problems
In a critical step that may lead to more effective HIV treatments, Harvard scientists have found that, in a small number of HIV patients, pre-existing mutations in the virus can cause it to develop resistance to the drugs used to slow the progression of the disease. By shedding new light on how resistance evolves, the study opens the door to the development of new, more effective treatments. (2012-06-07)

Longer breastfeeding with extended ART could reduce mother-to-child HIV transmission and improve infant survival
Giving antiretroviral drugs to HIV-infected mothers or their babies is highly effective at preventing HIV transmission through breast milk. However, stopping breastfeeding early (before six months) does not protect these children from HIV infection and significantly increases their likelihood of illness, growth problems, and death. (2012-04-25)

Longer breastfeeding along with antiretroviral drugs could lower HIV transmission to babies
New research finds that early weaning - stopping breastfeeding before six months - is of little, if any, protective value against HIV transmission nor is it safe for infant survival. (2012-04-25)

How can pediatric HIV be eliminated in Zimbabwe?
Eliminating new infant HIV infections in Zimbabwe will require not only improved access to antiretroviral medications but also support to help HIV-infected mothers continue taking their medication and safely reduce or eliminate breastfeeding, according to an article in the January issue of PLoS Medicine. (2012-01-10)

Prophylactic nevirapine to prevent mother-to-child HIV transmission can be safely used up to age 6 months
Rates of transmission of HIV from infected mothers to their newborn children are reduced if the children are given a daily oral dose of the antiretroviral drug nevirapine, a strategy that can be safely used until the child is six months old or the mother stops breastfeeding. (2011-12-22)

Latest antiretroviral drug against HIV-1 infection, rilpivirine, an effective alternative to first choice efavirenz, with fewer side effects
The latest antiretroviral drug against HIV-1 infection, rilpivirine, is a safe and effective alternative to the widely used efavirenz in combination with standard background therapy, in patients beginning HIV treatment for the first time. (2011-07-14)

Certain HIV medication associated with adrenal dysfunction in newborns of HIV-1 infected mothers
Infants of human immunodeficiency virus 1 (HIV-1) infected mothers who were treated before and after birth with the protease inhibitor lopinavir-ritonavir were more likely to experience adrenal dysfunction, including life-threatening adrenal insufficiency in premature infants, compared with a zidovudine-based regimen, according to a preliminary report in the July 6 issue of JAMA. (2011-07-05)

Prevention of mother-child transmission programs work but infants need checking for drug resistance
Genetic mutations that lead to antiretroviral (the drugs used to treat HIV/AIDS) resistance in HIV-infected infants may develop as a result of exposure to low doses of maternal antiretroviral drugs via breastfeeding rather than being acquired directly from the mother. (2011-03-29)

Latest findings of Dartmouth HIV/AIDS study could turn treatment 'on its head'
A clinical study of anti-HIV/AIDS medicines in the developing world is on the verge of turning (2011-03-03)

18th Conference on Retroviruses and Opportunistic Infections: Day 4 NIH highlights
Highlighted below are selected presentations from March 2 on research supported by the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, both components of the National Institutes of Health. (2011-03-03)

New drug regimens cut HIV spread from mother to infant
Pregnant women who are unaware that they have HIV miss the chance for drug treatment that can benefit not only their own health, but could also prevent them from transmitting the virus to their infants. When HIV is not diagnosed until women go into labor, their infants are usually treated soon after birth with the anti-HIV drug zidovudine, to prevent the infants from becoming infected with the virus. (2011-03-02)

6-month drug regimen cuts HIV risk for breastfeeding infants, NIH study finds
Giving breastfeeding infants of HIV-infected mothers a daily dose of the antiretroviral drug nevirapine for six months halved the risk of HIV transmission to the infants at age 6 months compared with giving infants the drug daily for six weeks, according to preliminary clinical trial data presented today at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. (2011-03-02)

Teens with HIV at high risk for pregnancy, complications
Teenage girls and young women infected with HIV get pregnant more often and suffer pregnancy complications more frequently than their HIV-negative peers, according to new research led by Johns Hopkins investigators. (2011-02-01)

Reducing HIV risk of breastfeeding with 3-drug prophylaxis
The risk of transmitting HIV to infants during breastfeeding can be halved with a triple-drug regimen taken by mothers. These findings indicate that prophylaxis with a three-drug regimen can safely replace older regimens in Africa, concludes the article published online first in Lancet Infectious Diseases. (2011-01-13)

New discoveries make it harder for HIV to hide from drugs
In the Journal of Biological Chemistry and Nature Structural & Molecular Biology, MU microbiologist and biochemist Stefan Sarafianos, Ph.D., reveals new findings that shed light on how HIV eludes treatment by mutating. His discoveries provide clues into HIV's mechanisms for resisting two main families of drugs. (2010-12-15)

OCTANE study influences revision of WHO guidelines for treating some HIV-infected women
Findings from a study, which appear in the Oct. 14, 2010, New England Journal of Medicine, helped influence the World Health Organization (WHO) to change its guidelines this year for the treatment of HIV-infected women who receive a single dose of the antiretroviral drug nevirapine to prevent HIV transmission to their babies. (2010-10-14)

NIH studies influence revision of WHO guidelines for treating HIV-infected women, infants
Two studies appearing in the Oct. 14, 2010, New England Journal of Medicine and funded by the National Institutes of Health helped influence the World Health Organization to change its guidelines this year for the treatment of HIV infection in certain women and children. (2010-10-13)

Nevirapine use may be beneficial for some HIV-infected children who have achieved viral suppression
HIV-infected children in South Africa who were exposed to the drug nevirapine at birth (used to help prevent mother-to-child HIV transmission) and then received a protease inhibitor (PI) for viral suppression achieved lower rates of viremia (virus in the blood stream) if they were switched to nevirapine, compared to children who continued on the PI-based regimen, according to a study in the Sept. 8 issue of JAMA. (2010-09-07)

A better way to treat HIV-infected children?
A new study involving 195 infants in South Africa found that children who were treated with protease inhibitors (PI) and then switched to nevirapine were more likely to maintain virus below the detection threshold of the test than infants who continued to receive PI. (2010-09-07)

Vanishing bile duct syndrome secondary to anti-retroviral therapy in HIV
Vanishing bile duct syndrome (VBDS) is an important cause of jaundice, and results from destruction of bile ducts in the liver. However, this syndrome is rare in patients with human immunodeficiency virus infection. Nevirapine, an anti-retroviral that is being increasingly used, was implicated as the cause of VBDS in a patient described in a recent report. (2010-07-30)

Many HIV-exposed infants in African countries not receiving medication to help prevent HIV
Only about half of infants born to HIV-infected mothers in some African countries receive a minimum preventive dose of the drug nevirapine to help reduce the risk of mother-to-child HIV transmission, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS. (2010-07-18)

Page 1 of 3 | 96 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.